It's a good question. I took that statement to mean that they are comparing OPRX to Humira specifically for the treatment of ulcerative colitis and not the other conditions that Humira also treats such as RA. Maybe they were trying to give investors more context into the potential success OPRX could have by mentioning an established drug that is generating major revenues?
The company really needs to step it up in terms of marketing and exposure. They need to do more conference calls to generate excitement and try to get more analyst coverage to give a rating on the stock and put this on more investor radars.
News 
Market Data 
Discover 
